
On July 29, 2024, Biointron achieved a "Mature" score on the Cybervadis assessment. This comprehensive assessment, which evaluated our entire organization and all functions, underscores our commitment to excellence in cybersecurity and risk management. CyberVadis is a leading global provider of independent cybersecurity assessment services, and their rigorous evaluation process includes international standards such as ISO 2700x, NIST Cybersecurity Framework, ICS Cybersecurity, and GDPR.
With an overall score of 868/1000, Biointron has been rated as mature. The overall CyberVadis benchmark score is 654/1000, and Biointron has surpassed all focus area and function scores of the average score from other assessed companies. The assessment demonstrates our perfect score of 1000 for 3rd party security management, which involves monitoring and managing the security risks associated with external vendors, partners, or service providers that have access to a company's data or systems. We also have mature scores for data privacy and data protection.
🔍 Why is this important for you?
A third-party cyber security risk assessment evaluates security practices to identify potential vulnerabilities that could pose a threat to an organization. This process involves reviewing the third party's policies, controls, and procedures to ensure they align with industry standards and regulatory requirements. By conducting such assessments, organizations can mitigate risks associated with data breaches, non-compliance, and operational disruptions, thereby safeguarding their sensitive information and maintaining the integrity of their cybersecurity posture.
The CyberVadis assessment helps streamline due diligence on third-party vendors, significantly reducing the risk of data breaches. In fact, a 2019 IBM and Ponemon Institute study found that 56% of organizations have faced data breaches caused by vendors.
At Biointron, we are dedicated to protecting our clients’ information through robust security management processes. Our adherence to a certified ISO 9001:2015 quality management system and our successful completion of cybersecurity assessments reflect our unwavering commitment to your security and trust.
On February 22, 2026, Biointron successfully completed its latest third-party cy……
Biointron, a specialized antibody contract research organization (CRO), has been……
The development of Biointron’s AbDrop, a scalable microfluidics-based platform f……
Recognition places Biointron among the top 35% of global performers in sustainab……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



